Oleoyl-estrone
Identification
- Generic Name
- Oleoyl-estrone
- DrugBank Accession Number
- DB04870
- Background
Oleoyl-estrone (OE) is a fatty acid ester of estrone. This hormone occurs naturally and is found circulating in various animal species and humans. It has been shown in animal studies to promote the loss of body fat while maintaining body protein storage, maintaining nitrogen balance. Body protein loss is an unpleasant effect of fat loss by the restriction of calories, and studies show that this drug appears to avoid this effect.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 534.8122
Monoisotopic: 534.407295594 - Chemical Formula
- C36H54O3
- Synonyms
- Estrone 3-oleate
- Estrone monooleate
- Estrone oleic acid ester
- OE
- Oleoyl estrone
- Oleoylestrone
- External IDs
- MP-101
Pharmacology
- Indication
For the treatment of obesity.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Oleoyl-estrone is a fatty acid ester of estrone, and may be directly involved in the control of body weight (PMID: 8782737).
- Mechanism of action
Based on extensive preclinical studies, it is believed that oleoyl-estrone (OE) works by a dual mechanism of action. Centrally, OE appears to act at the brain's hypothalamus, resetting the body's ponderostat, the “food control center” in the brain that detects and integrates signals that control both appetite and metabolic behavior. Peripherally, OE also causes reduced storage of fat in “white fat” tissue and allows skeletal muscle to use fat as an alternate energy source.
- Absorption
Orally available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- 17-Ketosteroids
- Adrenal Cortex Hormones
- Anti-Obesity Agents
- Drug Carriers
- Estradiol Congeners
- Estranes
- Estrenes
- Fatty Acids
- Fatty Acids, Monounsaturated
- Fatty Acids, Unsaturated
- Fused-Ring Compounds
- Gonadal Hormones
- Gonadal Steroid Hormones
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Ketosteroids
- Lipids
- Steroids
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Steroid esters
- Direct Parent
- Steroid esters
- Alternative Parents
- Estrane steroids / 17-oxosteroids / Phenanthrenes and derivatives / Tetralins / Ketones / Carboxylic acid esters / Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives
- Substituents
- 17-oxosteroid / Aromatic homopolycyclic compound / Benzenoid / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Estrane-skeleton / Hydrocarbon derivative / Ketone / Monocarboxylic acid or derivatives
- Molecular Framework
- Aromatic homopolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 64R56KMG1Z
- CAS number
- 180003-17-2
- InChI Key
- IMIPDPVHGGHVNH-YWVHRCQQSA-N
- InChI
- InChI=1S/C36H54O3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-35(38)39-29-20-22-30-28(27-29)19-21-32-31(30)25-26-36(2)33(32)23-24-34(36)37/h10-11,20,22,27,31-33H,3-9,12-19,21,23-26H2,1-2H3/b11-10-/t31-,32-,33+,36+/m1/s1
- IUPAC Name
- (3aS,3bR,9bS,11aS)-11a-methyl-1-oxo-1H,2H,3H,3aH,3bH,4H,5H,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-yl (9Z)-octadec-9-enoate
- SMILES
- [H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC(=O)CCCCCCC\C=C/CCCCCCCC)C=C3
References
- General References
- Sanchis D, Balada F, del Mar Grasa M, Virgili J, Peinado J, Monserrat C, Fernandez-Lopez JA, Remesar X, Alemany M: Oleoyl-estrone induces the loss of body fat in rats. Int J Obes Relat Metab Disord. 1996 Jun;20(6):588-94. [Article]
- Salas A, Remesar X, Esteve M: Oleoyl-estrone treatment activates apoptotic mechanisms in white adipose tissue. Life Sci. 2007 Jan 2;80(4):293-8. Epub 2006 Sep 30. [Article]
- External Links
- PubChem Compound
- 6918373
- PubChem Substance
- 175426878
- ChemSpider
- 5293576
- ZINC
- ZINC000014300189
- Wikipedia
- Oleoyl-estrone
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 3 Withdrawn Treatment SBS / Short Bowel Syndrome (SBS) / Short Gut / Short Gut Syndrome 1 2 Terminated Treatment Aggression / Agitation / Dementia / Dementia of the Alzheimer's Type / Psychosis 1 2 Unknown Status Treatment Obesity 2 Not Available Recruiting Supportive Care Coronavirus Disease 2019 (COVID‑19) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 4.87e-06 mg/mL ALOGPS logP 9.64 ALOGPS logP 11.23 Chemaxon logS -8 ALOGPS pKa (Strongest Basic) -7 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 43.37 Å2 Chemaxon Rotatable Bond Count 17 Chemaxon Refractivity 162.99 m3·mol-1 Chemaxon Polarizability 67.61 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9709 Caco-2 permeable + 0.7297 P-glycoprotein substrate Substrate 0.6692 P-glycoprotein inhibitor I Inhibitor 0.6415 P-glycoprotein inhibitor II Inhibitor 0.5314 Renal organic cation transporter Non-inhibitor 0.8248 CYP450 2C9 substrate Non-substrate 0.7902 CYP450 2D6 substrate Non-substrate 0.8958 CYP450 3A4 substrate Substrate 0.6873 CYP450 1A2 substrate Non-inhibitor 0.8287 CYP450 2C9 inhibitor Non-inhibitor 0.8072 CYP450 2D6 inhibitor Non-inhibitor 0.9151 CYP450 2C19 inhibitor Inhibitor 0.5344 CYP450 3A4 inhibitor Non-inhibitor 0.8284 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.542 Ames test Non AMES toxic 0.9253 Carcinogenicity Non-carcinogens 0.8829 Biodegradation Not ready biodegradable 0.9891 Rat acute toxicity 1.7534 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.876 hERG inhibition (predictor II) Non-inhibitor 0.617
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 259.1830116 predictedDarkChem Lite v0.1.0 [M-H]- 245.2488 predictedDeepCCS 1.0 (2019) [M+H]+ 259.4466116 predictedDarkChem Lite v0.1.0 [M+H]+ 247.14421 predictedDeepCCS 1.0 (2019) [M+Na]+ 252.80424 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2007 10:27 / Updated at June 12, 2020 16:52